Sign up USA
Proactive Investors - Run By Investors For Investors

Valeant gains on raising $2 billion in stock offering

Valeant gains on raising $2 billion in stock offering

Valeant Pharmaceuticals International Inc. (TSE:VRX), Canada’s largest drug-maker, advanced as much as 2 percent on Wednesday after saying it raised about $2 billion in an offering of common shares priced at $85 a share. 

The shares rose to as high as C$87.55 before trading at C$86.44, up 0.7 percent at 3:40 p.m. in Toronto, stretching this year’s gains to approximately 45 percent.

The Laval, Quebec-based company said in a statement late on Tuesday that it will use the proceeds to help fund its planned $8.7 billion acquisition of global eye-care company Bausch & Lomb Holdings Inc. The stock offering is expected to close by Monday.

The Bausch & Lomb acquisition is expected to close in the third quarter. Valeant had about 305.9 million shares outstanding as of April 30.

Meanwhile on Wednesday, Bloomberg News cited unidentified people as saying Valeant is seeking a $3.55 billion term loan B and a $500 million term A piece to support its purchase of Bausch.

 

 



Register here to be notified of future VRX Company articles
View full VRX profile

Valeant Pharmaceuticals Timeline

Related Articles

Benjamin Franklin wearing a medical mask
March 24 2016
Constellation has identified a significant market opportunity in healthcare billing management.
cells_56ab78cfbeec5.jpg
January 29 2016
A return to Nasdaq and ongoing commercial success promises to address a significant disconnect in the valuation of Pressure Bioscience...
picture of pregnant woman
October 10 2016
Stem cell therapies are tipped to be among the next great advances in the treatment of a range of life-threatening ailments and conditions.
Copyright © Proactiveinvestors.com, 2016. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC